ArticleTherapeutic advances in drug safety2026

Disproportionality analysis of off-label intravitreal bevacizumab in the FDA Adverse Event Reporting System database.

Homero Contreras-Salinas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.